Authors:
Alvarez, XA
Lombardi, VRM
Fernandez-Novoa, L
Garcia, M
Sampedro, C
Cagiao, A
Cacabelos, R
Windisch, M
Citation: Xa. Alvarez et al., Cerebrolysin (R) reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection, J NEUR TR-S, (59), 2000, pp. 281-292
Authors:
Cacabelos, R
Alvarez, A
Lombardi, A
Fernandez-Novoa, L
Corzo, L
Perez, P
Laredo, M
Pichel, V
Hernandez, A
Varela, M
Figueroa, J
Prous, J
Windisch, M
Vigo, C
Citation: R. Cacabelos et al., Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics, DRUGS TODAY, 36(7), 2000, pp. 415-499
Authors:
De Olano, M
Mesa, MD
Fernandez-Novoa, L
Corzo, L
Blanco, A
Cacabelos, R
Citation: M. De Olano et al., Angiotensin-converting-enzyme I/D polymorphism and angiotensinogen M235T polymorphism in cerebrovascular pathology, 1ST INTERNATIONAL CONGRESS ON VASCULAR DEMENTIA, 1999, pp. 207-210
Authors:
Alvarez, XA
Fernandez-Novoa, L
Sampedro, C
Lombardi, V
Windisch, M
Cacabelos, R
Citation: Xa. Alvarez et al., Neuroimmunotrophic effects of Cerebrolysin((R)) in an animal model of hippocampal degeneration induced by beta-amyloid, 1ST INTERNATIONAL CONGRESS ON VASCULAR DEMENTIA, 1999, pp. 233-237
Authors:
Cacabelos, R
Beyer, K
Lao, JI
Mesa, MD
Fernandez-Novoa, L
Citation: R. Cacabelos et al., Association of genetic risk factors in Alzheimer's disease and a novel mutation in the predicted TM2 domain of the presenilin-2 gene in late-onset AD, ALZHEIMER'S DISEASE AND RELATED DISORDERS, 1999, pp. 93-102